SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. The Brigham is acknowledged internationally for its expertise and innovation in patient care, biomedical research, and educational training programs for physicians, scientists, and health care professionals.
As viruses are implicated in the development of autoimmune diseases, there is the need to understand the effects of the current COVID-19 pandemic on the development of rheumatic autoimmune diseases. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19.
Positive polymerase chain reaction (PCR)-confirmed COVID-19 patients from the Brigham will be invited to partake in the year-long evaluation. Patients will be categorized by COVID-19 severity: mild (outpatient), moderate (inpatient, not ICU), and severe (ICU). Patients who elect to participate will be assessed with two validated questionnaires and tested using AVISE® bio...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).